Precision Oncology: Translating Discovery to the Clinic
Scientific Organizers: Klaus Hoeflich, Scott Lowe and Alice Shaw
Date: May 16 - 20, 2021
Location: Van Andel Institute, Grand Rapids, MI, USA
For important information on the coronavirus, please click here
The discovery of genomic and epigenetic alterations in individual cancers has led to a plethora of precision medicine innovations and therapeutic successes in oncology. Accordingly, cancer treatments have migrated away from the “one size fits all” approach. However, even as precision medicine is becoming more multi-disciplinary, progress is still hindered by insufficient collaboration between basic researchers, drug development programs, and physician scientists with broad expertise across cancer biology, genomics and other relevant fields. Therefore, this conference will bring together diverse experts from academic, pharma/biotech, medical and government sectors to discuss current challenges and future directions in precision oncology. In particular, the meeting will foster crosstalk between clinicians, cancer biologists and genomic scientists to identify and address key knowledge gaps that limit the advancement of new precision therapies. This conference program will cover topics such as novel genomic insights, therapeutically promising mechanisms and cancer drug targets, recent translational breakthroughs, and the incorporation of new diagnostic tools as companions to new precision treatments. The program will emphasize leading-edge advances in “reverse translation” technologies, such as liquid biopsies and single cell genomics, in addition to innovative, first-in-class approaches to novel therapeutics. Ultimately, the goal of the conference is to forge new collaborations across scientific and clinical boundaries, to advance the next generation of precision medicines against cancer.
We gratefully acknowledge additional support for this conference from: